MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test

Limited coverage is provided for the Envisia genomic classifier for ILD patients suspected of IPF when HRCT does not show a definitive UIP pattern and no known cause of ILD is identified. Testing is performed on transbronchial biopsy samples and is intended for patients—often older or at high surgical risk—where the assay's categorical UIP versus non‑UIP result may guide management and potentially avoid surgical lung biopsy.

"Envisia genomic classifier is covered for patients with interstitial lung disease (ILD) who are suspected of having idiopathic pulmonary fibrosis (IPF) and who do not have a definitive usual inters..."

Sign up to see full coverage criteria, indications, and limitations.